280 related articles for article (PubMed ID: 22328538)
1. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.
Beukelman T; Haynes K; Curtis JR; Xie F; Chen L; Bemrich-Stolz CJ; Delzell E; Saag KG; Solomon DH; Lewis JD;
Arthritis Rheum; 2012 Apr; 64(4):1263-71. PubMed ID: 22328538
[TBL] [Abstract][Full Text] [Related]
2. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.
Beukelman T; Xie F; Chen L; Baddley JW; Delzell E; Grijalva CG; Lewis JD; Ouellet-Hellstrom R; Patkar NM; Saag KG; Winthrop KL; Curtis JR;
Arthritis Rheum; 2012 Aug; 64(8):2773-80. PubMed ID: 22569881
[TBL] [Abstract][Full Text] [Related]
3. Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis.
Kok VC; Horng JT; Huang JL; Yeh KW; Gau JJ; Chang CW; Zhuang LZ
BMC Cancer; 2014 Aug; 14():634. PubMed ID: 25174953
[TBL] [Abstract][Full Text] [Related]
4. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan.
Hsin YC; Zhuang LZ; Yeh KW; Chang CW; Horng JT; Huang JL
PLoS One; 2015; 10(6):e0128768. PubMed ID: 26047099
[TBL] [Abstract][Full Text] [Related]
5. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.
Beukelman T; Xie F; Baddley JW; Chen L; Delzell E; Grijalva CG; Mannion ML; Patkar NM; Saag KG; Winthrop KL; Curtis JR;
Arthritis Rheum; 2013 May; 65(5):1384-9. PubMed ID: 23460423
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
7. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].
Horneff G
Z Rheumatol; 2010 Aug; 69(6):516-26. PubMed ID: 20532787
[TBL] [Abstract][Full Text] [Related]
8. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.
Horneff G; Klein A; Oommen PT; Hospach A; Foeldvari I; Feddersen I; Minden K
Clin Exp Rheumatol; 2016; 34(6):1113-1120. PubMed ID: 27749226
[TBL] [Abstract][Full Text] [Related]
9. Juvenile idiopathic arthritis and malignancy.
Ruperto N; Martini A
Rheumatology (Oxford); 2014 Jun; 53(6):968-74. PubMed ID: 24185766
[TBL] [Abstract][Full Text] [Related]
10. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Beukelman T; Xie F; Chen L; Horton DB; Lewis JD; Mamtani R; Mannion MM; Saag KG; Curtis JR
Ann Rheum Dis; 2018 Jul; 77(7):1012-1016. PubMed ID: 29440001
[TBL] [Abstract][Full Text] [Related]
11. A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.
Walters HM; Pan N; Lehman TJ; Adams A; Huang WT; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
Clin Rheumatol; 2015 Mar; 34(3):457-64. PubMed ID: 25227771
[TBL] [Abstract][Full Text] [Related]
12. Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
Shafferman A; Fontaine KR; Cron RQ; Beukelman T
J Rheumatol; 2014 Jan; 41(1):113-8. PubMed ID: 24293573
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
[TBL] [Abstract][Full Text] [Related]
14. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents.
Nordstrom BL; Mines D; Gu Y; Mercaldi C; Aquino P; Harrison MJ
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1357-64. PubMed ID: 22511558
[TBL] [Abstract][Full Text] [Related]
15. Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis.
Pohjankoski H; Kautiainen H; Lauri JV; Puolakka K; Rantalaiho V
Clin Rheumatol; 2020 Jan; 39(1):263-268. PubMed ID: 31346886
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of and factors associated to chronic kidney disease and hypertension in a cohort of children with juvenile idiopathic arthritis.
Gicchino MF; Di Sessa A; Guarino S; Miraglia Del Giudice E; Olivieri AN; Marzuillo P
Eur J Pediatr; 2021 Feb; 180(2):655-661. PubMed ID: 32860100
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
18. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
19. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
Nimmrich S; Horneff G
Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050
[TBL] [Abstract][Full Text] [Related]
20. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.
Mannion ML; Xie F; Curtis JR; Beukelman T
J Rheumatol; 2014 Oct; 41(10):2078-84. PubMed ID: 25086081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
